CTLA4 and small cell lung carcinoma: However, this trend of improved ORR was not observed in the ES-SCLC setting with median ORR only slightly improved with PD-1/PD-L1 inhibitors, but otherwise similar between the CTLA-4 inhibitor and combination ICI arms.